| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 4,590,174 | 7,721,393 | 4,252,290 | 6,089,126 |
| Accounts receivable, net of allowances | 1,079,055 | 4,049,111 | NaN | NaN |
| Inventory | 22,659,590 | 22,639,342 | 22,286,693 | 17,208,967 |
| Prepaid expenses | 3,356,882 | 3,535,287 | 1,395,490 | 1,313,176 |
| Total current assets | 31,685,701 | 37,945,133 | 27,934,473 | 24,611,269 |
| Operating lease right-of-use asset, net | 794,518 | 835,177 | 818,694 | 880,732 |
| Deposits | 38,062 | 38,062 | 38,062 | 38,062 |
| In-process research and development, net of accumulated amortization | 90,506,250 | 92,226,562 | 92,800,000 | 92,800,000 |
| Deferred financing costs | 169,252 | NaN | NaN | NaN |
| Goodwill | 9,346,796 | 9,346,796 | 9,346,796 | 9,346,796 |
| Total other assets | 100,060,360 | 101,611,420 | 102,184,858 | 102,184,858 |
| Total assets | 132,540,579 | 140,391,730 | 130,938,025 | 127,676,859 |
| Accounts payable | 9,453,803 | 11,021,412 | 13,693,692 | 10,094,042 |
| License payable | 17,650,000 | 18,250,000 | 22,650,000 | 28,400,000 |
| Note payable | NaN | 1,000,000 | 1,000,000 | 1,000,000 |
| Accrued expenses | 24,138,264 | 4,693,307 | 4,190,253 | 8,523,675 |
| Accrued compensation | 3,602,007 | 3,094,395 | 3,292,447 | 3,710,041 |
| Operating lease liability | 171,495 | 148,006 | 88,348 | 114,694 |
| Total current liabilities | 55,015,569 | 38,207,120 | 44,914,740 | 51,842,452 |
| Deferred tax liability | 7,803,790 | 8,035,000 | 7,770,760 | 7,506,520 |
| Operating lease liability noncurrent | 636,667 | 681,640 | 724,925 | 766,957 |
| Total liabilities | 63,456,026 | 46,923,760 | 53,410,425 | 60,115,929 |
| Common stock - 0.001 par value 250,000,000 shares authorized 22,376,427 and 18,067,744 shares issued and outstanding at march 31, 2026 and september 30, 2025, respectively | 22,376 | 22,376 | 18,068 | 14,475 |
| Additional paid-in capital | 329,775,214 | 326,960,700 | 306,336,239 | 295,888,916 |
| Accumulated deficit | -268,256,054 | -247,024,914 | -238,804,129 | -230,844,841 |
| Total citius pharmaceuticals, inc. stockholders equity | 61,541,536 | 79,958,162 | 67,550,178 | 65,058,550 |
| Non-controlling interest | 7,543,017 | 13,509,808 | 9,977,422 | 2,502,380 |
| Total equity | 69,084,553 | 93,467,970 | 77,527,600 | 67,560,930 |
| Total liabilities and equity | 132,540,579 | 140,391,730 | 130,938,025 | 127,676,859 |
Citius Pharmaceuticals, Inc. (CTXR)
Citius Pharmaceuticals, Inc. (CTXR)